Genomic and Transcriptomic Markers Associated with Response to Immune Checkpoint Blockade
Demographics (2)
- AGE - Subject age at enrollment (phv00492081.v1.p1)
- SEX - Biological sex (phv00492075.v1.p1)
Disease Events (11)
- AFFECTION_STATUS - Case control status of the subject with respect to stage III or stage IV melanoma (phv00492079.v1.p1)
- HISTOLOGICAL_TYPE - Histological type (phv00492094.v1.p1)
- IS_TUMOR - Tumor status (phv00492093.v1.p1)
- NBS_MB - SHERPA-predicted neoantigen burden per megabase (phv00492088.v1.p1)
- NEOPS_MB - SHERPA-predicted neoantigen burden per megabase with additional filtering accounting for deleterious alterations to the antigen presentation machinery (phv00492090.v1.p1)
- PD1_THERAPY - Therapy type administered to subject (phv00492084.v1.p1)
- PFS - Length of progression free survival (phv00492086.v1.p1)
- PROGRESSION_EVENT - Disease progression event (phv00492087.v1.p1)
- RESPONSE - Subject response to therapy (phv00492085.v1.p1)
- TMB - Tumor mutational burden (phv00492089.v1.p1)
- TUMOR_STAGE_AT_TREATMENT - Tumor stage at treatment start (phv00492083.v1.p1)
Race and Ethnicity (1)
- RACE - Self-reported race (phv00492080.v1.p1)
Other (8)
- ANALYTE_TYPE - Analyte Type (phv00492092.v1.p1)
- CONSENT - Consent group as determined by DAC (phv00492074.v1.p1)
- DISEASE_ORIGIN - Primary tumor site of origin (phv00492082.v1.p1)
- SAMPLE_ID - Sample ID (phv00492091.v1.p1)
- SAMPLE_ID - Sample ID (phv00492077.v1.p1)
- SUBJECT_ID - Subject ID (phv00492078.v1.p1)
- SUBJECT_ID - Subject ID (phv00492073.v1.p1)
- SUBJECT_ID - Subject ID (phv00492076.v1.p1)